Anemia Treatment Drugs Market By Type Of Anemia (Iron Deficiency Anemia, Thalassemia, Aplastic Anemia, Hemolytic Anemia, Sickle Cell Anemia, Pernicious Anemia), By Type Of Drug (Supplements, Antibiotics, Immunosuppresants, Bone Marrow Stimulants, Corticosteroids, Gene Therapy, Iron Chelating Agents) - Growth, Future Prospects And Competitive Landscape, 2018 – 2026

Industry Outlook

The anemia treatment drugs market accounted for a market value of US$ 23,155.8 million in 2017 and is projected to grow at a CAGR of 16.4% during the forecast period from 2018 to 2026. An abnormal decrease in the level of red blood cells, irregular red blood cell morphology, or inadequate concentration of hemoglobin in the blood results in anemia. Anemia is also caused by numerous nutritional and non-nutritional factors, such as infectious diseases (including malaria, soil-transmitted helminthiasis, hookworm, and tuberculosis). The World Health Organization (WHO) estimated that globally, anemia prevalence averaged 56%, with geographical variations in Europe and Asia, where the prevalence is in a range of 35% to 75%.

Market Synopsis

The presence of more than five molecules in clinical trials phase III owned by large pharmaceutical companies is expected to drive significant growth in the sickle cell anemia market in the coming years.

During the forecast period from 2018 to 2026, sickle cell anemia will grow at an exponential rate due to rising prevalence and awareness related to sickle cell anemia and the expected market entry of monoclonal antibodies and other biological drugs to treat sickle cell anemia efficiently. According to the World Health Organization (WHO), it is estimated that 312,000 children will be born worldwide with sickle cell anemia annually. Globally, the greatest burden exists in Sub-Saharan Africa, where 75% of the world's sickle cell disease occurs. However, the three major molecules targeting sickle cell anemia in clinical trial phase III are Rivipansel (Pfizer, Inc.), Voxelotor (Global Blood Therapeutics, Inc.), and GBT440 (Global Blood Therapeutics, Inc.). Thus, market approval of these drugs in the near future will assist the overall growth of the sickle cell anemia treatment market.

With the highest prevalence of the anemic population and increasing awareness about the diagnosis and treatment of anemia, Asia Pacific is expected to be the fastest-growing region in the global anemia treatment drugs market.

During the forecast period from 2018 to 2026, Asia-Pacific is expected to grow significantly due to rising prevalence and awareness related to anemia, the initiation of anemia awareness campaigns by government and non-government organizations, and the development of economic and healthcare infrastructure. According to the Sickle Cell Disease Coalition (SCDC), in 2016, India set a world record for screening 7.5 million people for SCD in a single day with the help of effective awareness campaigns carried out by both government and non-government organizations. The most significant development in Asia-Pacific was associated with advancements in screening, interventions, skilled healthcare providers, and medication accessibility. The strong drug pipeline for anemia treatment is also considered one of the key factors expected to assist the growth of the Asia-Pacific anemia treatment drugs market in the near future.

Periods of History and Forecast

The anemia treatment drugs market was analyzed considering current market trends for the base year of 2017, and based on future trends, CAGRs were calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

This report on the anemia treatment drugs market provides detailed information related to market dynamics, such as restraints, drivers, and opportunities, along with global trends. The report provides a broad summary of the global anemia treatment drugs market by segmenting the market based on anemia type, drug type, and geography. The objective of publishing this in-depth research report is to assist industry stakeholders in carrying out strategic decisions and implementation in the anemia treatment drugs market.

This report further describes the major qualitative assessment factors, including key market trends, market drivers, and market restraints, to assist in a better understanding of the global anemia treatment drugs market. The major players were analyzed based on their product offerings, market strategies, recent developments, and business strengths. The report also provides an attractive investment proposition based on the exhaustive geographical research carried out based on PESTEL analysis. Major companies profiled in the report include Pfizer, Inc., Amgen, Inc., Hoffmann-La Roche Ltd., Merck Sharp & Dohme Corp., Novartis AG, Janssen Pharmaceuticals, Bayer AG, AMAG Pharmaceuticals, GlaxoSmithKline plc, Akebia Therapeutics, Vifor Pharma Management, Ltd., and FibroGen, Inc., among others.

Key questions are answered in this report.

  • What are anemia treatment drugs, and how are they used to treat different types of anemia?
  • Which type of anemia is the largest segment in the global anemia treatment drug market?
  • What are the recent market trends and growth opportunities for the companies operating in the anemia treatment industry?
  • Which are the most attractive markets geographically for anemia treatment technology?
  • What are the pipeline analysis and overall future scenarios of the anemia treatment drug market?
  • What is the competitive landscape of the anemia treatment drug market?

Frequently Asked Questions: 

The market for Anemia Treatment Drugs is expected to reach US$ 23,155.8 Mn in 2026.

The Anemia Treatment Drugs market is expected to see significant CAGR growth over the coming years, at 16.4%.

The report is forecasted from 2018-2026.

The base year of this report is 2017.

Amgen, Inc.,Hoffmann-La Roche Ltd.,Novartis AG,Pfizer, Inc.,Janssen Pharmaceuticals, Inc. are some of the major players in the global market

Choose License Type
Trusted By
Published Date:  Feb 2019
Category:  Medical Devices
Report ID:   59597
Report Format:   PDF
Pages:   120
Rating:    4.1 (69)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
24/7 Research Support